Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IRMD
stocks logo

IRMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
21.60M
+11.39%
0.435
+8.75%
20.79M
+6.56%
0.415
+12.16%
21.83M
+6.96%
0.440
-2.22%
Estimates Revision
The market is revising Upward the revenue expectations for IRADIMED CORPORATION (IRMD) for FY2025, with the revenue forecasts being adjusted by 2.36% over the past three months. During the same period, the stock price has changed by 30.46%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.36%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.74%
In Past 3 Month
Stock Price
Go Up
up Image
+30.46%
In Past 3 Month
Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 93.920
sliders
Low
98.00
Averages
99.00
High
100.00
Current: 93.920
sliders
Low
98.00
Averages
99.00
High
100.00
Roth Capital
Buy
maintain
$90 -> $98
2025-11-04
Reason
Roth Capital
Price Target
$90 -> $98
2025-11-04
maintain
Buy
Reason
Roth Capital raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares after its Q3 earnings beat. Legacy pump sales remain strong despite the planned full launch of the next generation version in Q1, monitor sales accelerated in the quarter, and there could be nice uplift from the cross-selling the next gen pump into non-user hospitals, the analyst tells investors in a research note.
Lake Street
Buy
maintain
$75 -> $100
2025-11-03
Reason
Lake Street
Price Target
$75 -> $100
2025-11-03
maintain
Buy
Reason
Lake Street raised the firm's price target on iRadimed to $100 from $75 and keeps a Buy rating on the shares after a top and bottom line beat with revenue and EPS guidance increased in Q3. While acknowledging that shares trade at a premium valuation, the firm sees a record backlog providing near-term visibility and the new 3870 IV Pump launch driving growth acceleration in 2026, the analyst tells investors.
Roth Capital
Kyle Bauser
Buy
maintain
$90 -> $98
2025-11-03
Reason
Roth Capital
Kyle Bauser
Price Target
$90 -> $98
2025-11-03
maintain
Buy
Reason
Roth Capital analyst Kyle Bauser raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares, citing higher forward estimates and confidence in the business after the company reported Q3 sales and EPS above the firm's and consensus estimates and raised full-year guidance.
Roth Capital
Kyle Bauser
initiated
$90
2025-10-31
Reason
Roth Capital
Kyle Bauser
Price Target
$90
2025-10-31
initiated
Reason
Roth Capital analyst Kyle Bauser resumed coverage of iRadimed with a Buy rating and $90 price target. The firm expects the company to benefit from the launch of its next-gen non-magnetic IV infusion pump. The pump has "significant enhancements" and a premium selling price versus the older version, the analyst tells investors in a research note.
Roth MKM
Jason Wittes
Strong Buy
Reiterates
$60 → $72
2025-02-14
Reason
Roth MKM
Jason Wittes
Price Target
$60 → $72
2025-02-14
Reiterates
Strong Buy
Reason
Roth MKM raised the firm's price target on iRadimed to $72 from $60 and keeps a Buy rating on the shares. The company reported solid Q4 revenue of $19.4M, representing an 11% y/y increase while beating the firm's estimate and consensus of $19.1M as well as previously issued guidance of $19.2M-$19.4M for FY24, the analyst tells investors in a research note. Monitoring system bookings also improved in Q4, signaling early traction from iRadimed's renewed salesforce focus on this product category, the firm adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for IRadimed Corp (IRMD.O) is 52.18, compared to its 5-year average forward P/E of 37.71. For a more detailed relative valuation and DCF analysis to assess IRadimed Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
37.71
Current PE
52.18
Overvalued PE
47.30
Undervalued PE
28.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.51
Current PS
0.00
Overvalued PS
10.11
Undervalued PS
6.92
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

IRMD News & Events

Events Timeline

(ET)
2025-11-03
08:33:38
iRadimed Projects FY25 EPS Between $1.84 and $1.88
select
2025-11-03
08:33:19
iRadimed Projects Q4 EPS Between 47c and 51c
select
2025-11-03
08:32:41
iRadimed Announces Q3 Earnings Per Share of 47 Cents, Up from 43 Cents Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Transcript of IRadimed (IRMD) Earnings Call for Q3 2025
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
8.0
11-12NASDAQ.COM
Upcoming Ex-Dividend Dates for Duke Energy, American States Water, and iRadimed

  • Upcoming Ex-Dividend Dates: Duke Energy Corp (DUK), American States Water Co (AWR), and iRadimed Corp (IRMD) will trade ex-dividend on 11/14/25, 12/2/25, and 11/25/25 respectively, with dividends of $1.065, $0.504, and $0.17.

  • Expected Price Adjustments: Following the ex-dividend dates, shares of DUK, AWR, and IRMD are expected to open lower by approximately 0.86%, 0.66%, and 0.20% respectively.

  • Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 3.44% for Duke Energy, 2.66% for American States Water, and 0.80% for iRadimed, reflecting their historical dividend stability.

  • Current Trading Performance: As of Wednesday trading, Duke Energy shares are up 0.6%, American States Water shares are up 1.1%, while iRadimed shares are down 1.7%.

[object Object]
Preview
4.5
11-10Newsfilter
IRADIMED CORPORATION Recognized in TIME's 2026 List of America's Growth Leaders

  • Recognition: Iradimed Corporation has been named one of America's Growth Leaders for 2026 by TIME, ranking 79th among 501 companies recognized for outstanding growth based on revenue, financial stability, and stock performance.

  • Company Performance: The company has achieved 17 consecutive quarters of record revenue, reflecting its commitment to innovation and operational excellence in the MRI-compatible medical device market.

  • Innovative Products: Iradimed is known for its MRidium® MRI-compatible IV infusion pump and the 3880 MRI-compatible patient vital signs monitoring system, both designed to operate safely in MRI environments, enhancing patient care during procedures.

  • Methodology: The ranking was determined through a rigorous evaluation by TIME and Statista, focusing on revenue growth, financial stability, and stock performance, with a maximum score of 100 points awarded to the top companies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IRadimed Corp (IRMD) stock price today?

The current price of IRMD is 93.92 USD — it has increased 0.79 % in the last trading day.

arrow icon

What is IRadimed Corp (IRMD)'s business?

IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.

arrow icon

What is the price predicton of IRMD Stock?

Wall Street analysts forecast IRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IRadimed Corp (IRMD)'s revenue for the last quarter?

IRadimed Corp revenue for the last quarter amounts to 21.20M USD, increased 15.69 % YoY.

arrow icon

What is IRadimed Corp (IRMD)'s earnings per share (EPS) for the last quarter?

IRadimed Corp. EPS for the last quarter amounts to 0.43 USD, increased 7.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for IRadimed Corp (IRMD)'s fundamentals?

The market is revising Upward the revenue expectations for IRADIMED CORPORATION (IRMD) for FY2025, with the revenue forecasts being adjusted by 2.36% over the past three months. During the same period, the stock price has changed by 30.46%.
arrow icon

How many employees does IRadimed Corp (IRMD). have?

IRadimed Corp (IRMD) has 160 emplpoyees as of December 05 2025.

arrow icon

What is IRadimed Corp (IRMD) market cap?

Today IRMD has the market capitalization of 1.17B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free